<DOC>
	<DOC>NCT00681031</DOC>
	<brief_summary>Primary objective: To demonstrate whether or not ZOSTAVAX® at minimum release specification approaching expiry potency elicits an acceptable Varicella-Zoster Virus (VZV) antibody fold rise (measured by gpELISA) from pre-vaccination to 4 weeks post-vaccination Secondary objectives: To describe the safety profile of ZOSTAVAX® at minimum release specification approaching expiry potency</brief_summary>
	<brief_title>Zostavax® at Minimum Release Specification Approaching Expiry</brief_title>
	<detailed_description />
	<mesh_term>Herpes Zoster</mesh_term>
	<criteria>Subject of either gender aged ≥50 years Positive history of varicella or residence for &gt;30 years in a country with endemic VZV infection All females must be postmenopausal or have a negative serum or urine pregnancy test or acceptable method of birth control for three months after vaccination Subject having signed the informed consent form prior to any study procedure Subject febrile within 72 hours prior to vaccination Subject with a prior history of Herpes Zoster clinically diagnosed by a physician Subject has previously received a varicella or zoster vaccine Exposure to varicella or herpeszoster within 4 weeks prior to vaccination Subject received any other live virus vaccine within 4 weeks prior to vaccination, or is expected to receive any other live virus vaccine during the study Subject received any inactivated vaccine within 2 weeks prior to vaccination, or is expected to receive any inactivated vaccine during the study Subject is treated with immunoglobulins or any blood products, other than autologous blood transfusion, given during the 5 months prior to vaccination or is expected to be treated during the study Subject is taking any non topical antiviral therapy with activity against herpesviruses. Subject is on immunosuppressive therapy Subject has known or suspected immune dysfunction caused by a medical condition, or any other cause Subject has a history of hypersensitivity reaction or anaphylactoid reaction to any vaccine component, including gelatin or neomycin Subject with known active tuberculosis Subject with significant underlying illness preventing completion of the study</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>